The healthcare sector has been lagging the nine other main sectors since the beginning of 2019. The Healthcare Select Sector SPDR (NYSE: XLV) gained 9.24% from the beginning of the year through July 5 and it is the only sector SPDR that has gained less than 10%. The sector has been in the political spotlight to some degree as politicians on both sides of the aisle have been pointing at drug costs as a problem.
One particular exchange-traded fund that caught my eye was the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB). The fund has been trending lower since last September and there is a trend line that connects the highs from then with highs from March and April. The fund just hit the trend line last week and then turned lower.
The ETF saw its 10-day RSI and its daily stochastic readings hit overbought levels last week before turning lower. The stochastic readings just made a bearish crossover on July 5.
The Tickeron Trend Prediction Engine generated a bearish signal for the IBB on July 5 and it calls for a decline of at least 4% within the next month. The signal showed a confidence level of 75% and past predictions on the fund have been successful 85% of the time.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on May 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 18, 2026. You may want to consider a long position or call options on XLV as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XLV just turned positive on May 12, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
XLV moved above its 50-day moving average on June 03, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 268 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for XLV moved out of overbought territory on June 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for XLV moved below the 200-day moving average on May 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XLV broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Category Health